Taxanes

A cornerstone of treatment for metastatic breast cancer

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Taxanes currently approved for use in metastatic breast cancer (MBC) consist of paclitaxel, docetaxel, and nanoparticle albumin-bound paclitaxel. The taxanes are the most active single agents in MBC, and their use has contributed to improved survival in this setting. Differences between conventional paclitaxel and docetaxel include absence of dose response for paclitaxel versus a significant dose response for docetaxel and the ability to give paclitaxel on a weekly versus every-3-week schedule. Studies of taxanes in combination with anthracyclines in first-line treatment have shown improved response rates and time to disease progression; no definitive survival benefit has been shown with combination therapy compared with single-agent taxane therapy or among various combination regimens, except with taxane combinations involving capecitabine or gemcitabine in anthracycline-pretreated patients. Thus, the choice of taxane singlets, doublets, or triplets in first-line therapy depends on physician judgment and patient and disease characteristics. Drawbacks of conventional taxane formulations include the need for solvents, which add substantial toxicity to treatment and may compromise efficacy.

Original languageEnglish (US)
Pages (from-to)3-6
Number of pages4
JournalCommunity Oncology
Volume5
Issue number7 SUPPL. 8
StatePublished - Jul 1 2008

Fingerprint

docetaxel
Taxoids
Paclitaxel
Breast Neoplasms
Anthracyclines
gemcitabine
Therapeutics
Aptitude
Survival
Nanoparticles
Disease Progression
Appointments and Schedules
Physicians
taxane

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Taxanes : A cornerstone of treatment for metastatic breast cancer. / Schwartzberg, Lee.

In: Community Oncology, Vol. 5, No. 7 SUPPL. 8, 01.07.2008, p. 3-6.

Research output: Contribution to journalReview article

@article{61cc662293c94638bc8e226e5533dc02,
title = "Taxanes: A cornerstone of treatment for metastatic breast cancer",
abstract = "Taxanes currently approved for use in metastatic breast cancer (MBC) consist of paclitaxel, docetaxel, and nanoparticle albumin-bound paclitaxel. The taxanes are the most active single agents in MBC, and their use has contributed to improved survival in this setting. Differences between conventional paclitaxel and docetaxel include absence of dose response for paclitaxel versus a significant dose response for docetaxel and the ability to give paclitaxel on a weekly versus every-3-week schedule. Studies of taxanes in combination with anthracyclines in first-line treatment have shown improved response rates and time to disease progression; no definitive survival benefit has been shown with combination therapy compared with single-agent taxane therapy or among various combination regimens, except with taxane combinations involving capecitabine or gemcitabine in anthracycline-pretreated patients. Thus, the choice of taxane singlets, doublets, or triplets in first-line therapy depends on physician judgment and patient and disease characteristics. Drawbacks of conventional taxane formulations include the need for solvents, which add substantial toxicity to treatment and may compromise efficacy.",
author = "Lee Schwartzberg",
year = "2008",
month = "7",
day = "1",
language = "English (US)",
volume = "5",
pages = "3--6",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "7 SUPPL. 8",

}

TY - JOUR

T1 - Taxanes

T2 - A cornerstone of treatment for metastatic breast cancer

AU - Schwartzberg, Lee

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Taxanes currently approved for use in metastatic breast cancer (MBC) consist of paclitaxel, docetaxel, and nanoparticle albumin-bound paclitaxel. The taxanes are the most active single agents in MBC, and their use has contributed to improved survival in this setting. Differences between conventional paclitaxel and docetaxel include absence of dose response for paclitaxel versus a significant dose response for docetaxel and the ability to give paclitaxel on a weekly versus every-3-week schedule. Studies of taxanes in combination with anthracyclines in first-line treatment have shown improved response rates and time to disease progression; no definitive survival benefit has been shown with combination therapy compared with single-agent taxane therapy or among various combination regimens, except with taxane combinations involving capecitabine or gemcitabine in anthracycline-pretreated patients. Thus, the choice of taxane singlets, doublets, or triplets in first-line therapy depends on physician judgment and patient and disease characteristics. Drawbacks of conventional taxane formulations include the need for solvents, which add substantial toxicity to treatment and may compromise efficacy.

AB - Taxanes currently approved for use in metastatic breast cancer (MBC) consist of paclitaxel, docetaxel, and nanoparticle albumin-bound paclitaxel. The taxanes are the most active single agents in MBC, and their use has contributed to improved survival in this setting. Differences between conventional paclitaxel and docetaxel include absence of dose response for paclitaxel versus a significant dose response for docetaxel and the ability to give paclitaxel on a weekly versus every-3-week schedule. Studies of taxanes in combination with anthracyclines in first-line treatment have shown improved response rates and time to disease progression; no definitive survival benefit has been shown with combination therapy compared with single-agent taxane therapy or among various combination regimens, except with taxane combinations involving capecitabine or gemcitabine in anthracycline-pretreated patients. Thus, the choice of taxane singlets, doublets, or triplets in first-line therapy depends on physician judgment and patient and disease characteristics. Drawbacks of conventional taxane formulations include the need for solvents, which add substantial toxicity to treatment and may compromise efficacy.

UR - http://www.scopus.com/inward/record.url?scp=48249138396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249138396&partnerID=8YFLogxK

M3 - Review article

VL - 5

SP - 3

EP - 6

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 7 SUPPL. 8

ER -